Floatz logo

Ctc-501

Movement Disorders

Merck Sharp & Dohme LLCPhase 2Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

7 Active assets in the Movement Disorders cohort.

Asset / SponsorPhaseRating
LEVODOPA
MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
Phase 4BBB
1H-INDOLE-1-CARBOXYLIC ACID, OCTAHYDRO-4-HYDROXY-4-((3-METHYLPHENYL)ETHYNYL)-, METHYL ESTER, (3AR,4S,7AR)-
Novartis Pharmaceuticals
Phase 2BB
BACILLUS LICHENIFORMIS
Beijing Friendship Hospital
Phase 4BB
Bifidobacterium
Beijing Friendship Hospital
Phase 4BB
Live Combined Bifidobacterium
Beijing Friendship Hospital
Phase 4BB

View all 21 →

Same molecule, other indications

Ctc-501 is also rated in:

Parkinson diseaseDormant
BBB
Indicative ·
72 / 100
View asset →
bipolar disorderDormant
BB
Indicative ·
68 / 100
View asset →
adrenoleukodystrophyDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →